Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
  • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
  • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
  • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
  • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
  • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides

Definitions

• the present invention relates to a method for inhibiting the modulation of DNA caused by mutant p53.
• the invention further relates to a system for identifying substances which are suitable for such an inhibition.
• a protein called p53 is present in cells. This is a tumor suppressor that is activated when DNA is damaged. It then binds to promoters of target genes and activates their transcription. As a result, the cells stop growing with subsequent repair of the DNA damage or the death of the cells.
• p53 is mutated in many tumors. In this form, it often has no tumor suppressor activity. Rather, it even presents itself as a protein that has oncogenic properties.
• Various attempts have been made to inhibit mutant p53 (hereinafter referred to as mut p53) in its oncogenic properties. However, these attempts did not lead to satisfactory results.
• the object of the present invention is therefore to provide an agent with which mut p53 is examined and, if appropriate, in its oncogenic agents
• the present invention thus relates to a method for inhibiting the modulation of DNA caused by mut p53, comprising the inhibition of the binding of mut p53 to DNA with strand separation potential.
• the present invention is based on the knowledge of the applicant that mut p53, but not wild-type p53, can cause a modulation of a DNA that has a strand separation potential. He found that such DNA is common and is often found in MAR DNA.
• MAR Microx Attachment Region
• DNA refers to regulatory elements of higher order of chromatin, by which chromatin is divided into topologically independent "loops", which enables independent spatial and temporal regulation of gene expression and DNA replication.
• DNA with strand separation potential often comprises the sequence AATATATTT or a variation thereof. In addition to the sequence mentioned, the DNA often also has other AT-rich regions.
• the modulation of the DNA can be different, for example a solid complex of mut p53 and the DNA or a strand separation of these. He found that the modulation is often a strand separation if the specified sequence and possibly the adjacent sequences have an overall AT character. On the other hand, the modulation often shows up as a solid complex when the
• these findings are used for a method for inhibiting modulation of DNA caused by mut p53.
• One such method involves inhibiting mut p53 binding to DNA with strand separation potential.
• mut p53 encompasses any or part of p53 that can bind to DNA with strand separation potential.
• p53 can be one which has a mutated core domain and / or a mutated C terminus. Examples of such p53 mutants are Pro273 p53 and MethA p53. Mut p53 can also be one that works together with another
• DNA with strand separation potential encompasses any DNA which can be modulated by mut p53.
• the modulation can be different, for example a solid complex of mut p53 and a DNA with strand separation potential or a strand separation thereof.
• the DNA with strand separation potential can be one which contains one or more copies of the
• the DNA can also comprise further AT-rich regions.
• a DNA with strand separation potential is preferably found in MAR-DNA.
• binding encompasses any manner in which mut p53
• the binding can be one in which mut p53 binds directly to the DNA.
• the bond can also be one in which mut p53 is indirect, i.e. about other factors, such as proteins, binds to DNA.
• inhibitor encompasses any manner in which the binding of mut p53 to DNA with strand separation potential can be inhibited.
• the type of inhibition will depend on whether the binding of mut p53 to the DNA is direct or indirect. With indirect binding, i.e. Other factors, such as proteins, can be used for inhibition by substances which inhibit the other factors. Substances that inhibit mut p53 can also be added. If mut p53 is bound directly to the DNA, it makes sense to use substances that inhibit mut p53. Such substances can e.g. be those that inhibit a mutated core domain of p53 and / or a mutated C-terminus of p53. Examples of such
• Substances are the antibodies PAb 240 and PAb 421.
• a system for identifying substances which are suitable for inhibiting modulation of DNA caused by mut p53.
• Such a system includes mut p53 and a DNA
• the above statements apply accordingly to individual components of the system.
• a modulation of DNA or its inhibition can be determined by conventional methods. For example, DNA strand separation or complex formation and their inhibition by an EMSA
• Electrophoretic Mobility Shift Assay (“Electrophoretic Mobility Shift Assay”) test can be determined. For this purpose, it makes sense to incubate mut p53 with labeled, double-stranded DNA, which has a strand separation potential, and to separate the mixture electrophoretically, as a result of which the formation of single-stranded DNA or a complex and their inhibitions become visible.
• Such a modulation can be a solid complex of mut p53 and a DNA with strand separation potential or a DNA strand separation thereof.
• the modulation of DNA plays a major role in many processes in the cell. For example, DNA strand separation is an essential step in the expression of genes and the replication of DNA. DNA strand separation is subject to strong control. This control is overridden by mut p53. This clears the way for the cell to degenerate, i.e. can lead to tumor formation.
• the present invention it is possible to intervene therapeutically in diseases in which mut p53 causes a modulation of DNA.
• diseases are especially tumor diseases.
• the present invention is characterized in that it creates the possibility of identifying substances which are suitable for the inhibition of modulation of DNA caused by mut p53, in particular in tumors. Such substances are also an object of the present invention.
• Fig. 2 shows the DNA strand separation caused by mut p53
• FIG. 3 shows the complex formation caused by mut p53 in MAR5 DNA
• FIG. 4 shows the complex formation caused by mut p53 in MAR7 and MAR8 DNA
• Fig. 5 shows the inhibition of DNA strand separation caused by mut p53 in MARI-DNA.
• the modulation of DNA is shown in the form of a DNA strand separation or complex formation.
• Enhancer region of the gene for the heavy immunoglobulin chain lies two MAR regions were designed in the form of oligonucleotides. It was MARI, i.e. 3 'flanking region of the enhancer, and MARII, i.e. 5 'flanking region of the enhancer.
• the oligonucleotides had the following sequences:
• MARI has the sequence AATATATTT given above. MARII shows a variation of this sequence, whereby the overall AT character is not changed.
• oligonucleotides were designed which have variations of MARI in such a way that the overall AT character is weakened. These oligonucleotides had the following sequences: MAR6: ACTATGCTT MAR7: GCTCTCTTT
• oligonucleotides were designed which have the sequence of MARI together with adjacent "GC clamps".
• the overall AT character was weakened by the "GC clamps”.
• the oligonucleotides were synthesized, 32p-end labeled, and annealed to give them double-stranded. These were incubated with wild type p53 or mut p53, eg MethA p53 or Pro 273 p53, and subjected to an EMSA test. The procedure was as follows:
• mut p53 e.g. MethA p53 or Pro 273 p53
• a modulation of DNA e.g. Strand separation or complex formation in DNA with strand separation potential.
• an agent which inhibits the binding of mut p53 to a DNA with strand separation potential such as the antibodies PAb 421 and PAb 240, can be inhibited by DNA strand separation induced by mut p53.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• General Health & Medical Sciences (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• Zoology (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• Wood Science & Technology (AREA)
• Toxicology (AREA)
• Analytical Chemistry (AREA)
• Physics & Mathematics (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Gastroenterology & Hepatology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Engineering & Computer Science (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Investigating Or Analysing Biological Materials (AREA)
• Peptides Or Proteins (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=7855657

Family Applications (1)

Country Status (13)

Families Citing this family (1)

Family Cites Families (2)

• 1998
  • 1998-01-26 DE DE19802792A patent/DE19802792A1/de not_active Withdrawn
• 1999
  • 1999-01-22 CN CN99802374A patent/CN1289373A/zh active Pending
  • 1999-01-22 RU RU2000121564/13A patent/RU2235786C2/ru not_active IP Right Cessation
  • 1999-01-22 SK SK1105-2000A patent/SK11052000A3/sk unknown
  • 1999-01-22 DE DE19980080T patent/DE19980080D2/de not_active Ceased
  • 1999-01-22 KR KR10-2000-7008117A patent/KR100413929B1/ko not_active IP Right Cessation
  • 1999-01-22 PL PL99342399A patent/PL342399A1/xx not_active Application Discontinuation
  • 1999-01-22 JP JP2000528710A patent/JP2002507389A/ja active Pending
  • 1999-01-22 BR BR9907725-6A patent/BR9907725A/pt not_active IP Right Cessation
  • 1999-01-22 EP EP99910089A patent/EP1049810A2/de not_active Withdrawn
  • 1999-01-22 CA CA002318313A patent/CA2318313A1/en not_active Abandoned
  • 1999-01-22 AU AU29200/99A patent/AU755775B2/en not_active Ceased
  • 1999-01-22 WO PCT/DE1999/000221 patent/WO1999037803A2/de not_active Application Discontinuation
• 2000
  • 2000-07-21 NO NO20003762A patent/NO20003762D0/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events